NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

NeurogesX, Inc. has announced the initiation of its Phase 1 clinical trial (study C203) of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

The randomized, single-blind Phase 1 trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials.

NeurogesX expects to complete the trial by the end of 2008.

Anthony DiTonno, President and CEO of NeurogesX, commented, "The initiation of this Phase 1 trial of NGX-1998 marks a significant step in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We believe that our Phase 1 trial will provide us with important information that will help shape the design of further studies with the product candidate. We are pleased with the Company's progress with NGX-1998 advancing in the clinic and NGX-4010 under regulatory review in Europe and approaching NDA submission in the United States."